Clinical Trials Logo

Clinical Trial Summary

This study will test the safety of MSLN-targeted CAR-T cells at different doses to find the safest dose to give to people with MPM. The researchers want to see what effects, if any, the study treatment has on people with this type of cancer. This study is the first time that an MSLN-targeted CAR-T cell treatment with an anti-PD1 component is being given to people.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04577326
Study type Interventional
Source Memorial Sloan Kettering Cancer Center
Contact Roisin O'Cearbhaill, MD
Phone 646-888-4227
Email cart@mskcc.org
Status Recruiting
Phase Phase 1
Start date September 30, 2020
Completion date September 30, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Withdrawn NCT02661659 - A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy Phase 1
Active, not recruiting NCT05228015 - Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors Phase 1
Completed NCT01773655 - Clinical and Histopathologic Characteristics of BAP1 Mutations
Completed NCT02555007 - Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM Phase 1